$25,637.64 consulting Payment -- AstraZeneca to Dr. Amanda Lewis
Nephrologist Dr. Amanda Lewis Receives $25,637 Consulting Fee from AstraZeneca for Ibrance
This page provides a detailed analysis of a $25,637.64 consulting payment from AstraZeneca to Dr. Amanda Lewis. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $25,637.64 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | AstraZeneca |
| Physician | Dr. Amanda Lewis |
| NPI Number | 1247583958 |
| Physician Specialty | Nephrology |
| Location | City, WI |
| Date of Payment | 2025-04-19 |
| Related Drug/Device | Ibrance |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
AstraZeneca made a $25.6K consulting payment to Amanda Lewis, a Nephrology specialist in City, WI. The payment was associated with Ibrance. The payment of $25,637.64 to Dr. Amanda Lewis for consulting services related to Ibrance is a significant amount. This payment was made by AstraZeneca, a major pharmaceutical company, for consulting services. The payment date is in the future (April 19, 2025), indicating a planned engagement.
Patient Guidance: What This Payment Means for You
If you are a patient, understand that your doctor may receive payments for consulting services from pharmaceutical companies, which can help inform drug development and education. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
While consulting fees are common in the pharmaceutical industry, the amount of $25,637.64 for a single engagement may be higher than typical for some specialties, though it could be justified by the scope of work in Nephrology related to specific drugs.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- consulting-fees
- nephrology
- astrazeneca
- ibrance
- physician-compensation
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $25.6K payment for?
This was a consulting payment of $25.6K from AstraZeneca to Amanda Lewis, categorized as "Consulting Fee". It was associated with Ibrance. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Amanda Lewis accept pharmaceutical money?
Yes, Amanda Lewis received this $25.6K payment from AstraZeneca. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Amanda Lewis's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $25.6K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Nephrology?
To compare this payment against Nephrology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Nephrology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Amanda Lewis's relationship with AstraZeneca?
The payment is specifically for 'Consulting Fee' under the 'consulting' payment type. This $25.6K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Nephrology?
The drug associated with this payment is Ibrance, a targeted therapy.
What should patients do after learning about this payment?
If you are a patient, understand that your doctor may receive payments for consulting services from pharmaceutical companies, which can help inform drug development and education.
What else should I know about this consulting payment?
Dr. Lewis's specialty is Nephrology, which may or may not be directly related to Ibrance's primary indications.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.